+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cerebral Palsy - Pipeline Review, H1 2020

  • ID: 4911663
  • Drug Pipelines
  • January 2020
  • 47 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • CytoDel Inc
  • FamiCord Group
  • Hope Biosciences LLC
  • Kashiv BioSciences LLC
  • Meridigen Biotech Co Ltd
  • Revance Therapeutics Inc
  • MORE
Cerebral Palsy - Pipeline Review, H1 2020

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Cerebral Palsy - Pipeline Review, H1 2020, provides an overview of the Cerebral Palsy (Central Nervous System) pipeline landscape.

Cerebral palsy is a group of disorders that can involve brain and nervous system functions, such as movement, learning, hearing, seeing, and thinking. Symptoms include muscles that are very tight and do not stretch, abnormal walk (gait), arms tucked in toward the sides, knees crossed or touching, legs make scissors movements, walk on the toes, speech problems (dysarthria), hearing or vision problems and pain. Treatment includes anticonvulsants and muscle relaxants.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Cerebral Palsy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Cerebral Palsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cerebral Palsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cerebral Palsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Unknown stages are 3, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Phase 0 and Preclinical stages comprises 1 and 1 molecules, respectively.

Cerebral Palsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cerebral Palsy (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Cerebral Palsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cerebral Palsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cerebral Palsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cerebral Palsy (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cerebral Palsy (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cerebral Palsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • CytoDel Inc
  • FamiCord Group
  • Hope Biosciences LLC
  • Kashiv BioSciences LLC
  • Meridigen Biotech Co Ltd
  • Revance Therapeutics Inc
  • MORE
  • Introduction
  • Report Coverage
  • Cerebral Palsy - Overview
  • Cerebral Palsy - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Cerebral Palsy - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Cerebral Palsy - Companies Involved in Therapeutics Development
  • CytoDel Inc
  • FamiCord Group
  • Hope Biosciences LLC
  • iCELL Biotechnology Co Ltd
  • Kashiv BioSciences LLC
  • Meridigen Biotech Co Ltd
  • Revance Therapeutics Inc
  • Teva Pharmaceutical Industries Ltd
  • Cerebral Palsy - Drug Profiles
  • ANGES-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cyto-012 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cerebral Palsy - Dormant Projects
  • Cerebral Palsy - Product Development Milestones
  • Featured News & Press Releases
  • May 01, 2019: Teva to present new data on AUSTEDO at 71st Annual Meeting of the American Academy of Neurology
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Cerebral Palsy, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Cerebral Palsy - Pipeline by CytoDel Inc, H1 2020
  • Cerebral Palsy - Pipeline by FamiCord Group, H1 2020
  • Cerebral Palsy - Pipeline by Hope Biosciences LLC, H1 2020
  • Cerebral Palsy - Pipeline by iCELL Biotechnology Co Ltd, H1 2020
  • Cerebral Palsy - Pipeline by Kashiv BioSciences LLC, H1 2020
  • Cerebral Palsy - Pipeline by Meridigen Biotech Co Ltd, H1 2020
  • Cerebral Palsy - Pipeline by Revance Therapeutics Inc, H1 2020
  • Cerebral Palsy - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2020
  • Cerebral Palsy - Dormant Projects, H1 2020
List of Figures
  • Number of Products under Development for Cerebral Palsy, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • CytoDel Inc
  • FamiCord Group
  • Hope Biosciences LLC
  • iCELL Biotechnology Co Ltd
  • Kashiv BioSciences LLC
  • Meridigen Biotech Co Ltd
  • Revance Therapeutics Inc
  • Teva Pharmaceutical Industries Ltd
Note: Product cover images may vary from those shown
Adroll
adroll